Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Impact of early diagnosis on clinical characteristics of an Italian sample of people with multiple sclerosis recruited online.

Lavorgna L, Borriello G, Esposito S, Abbadessa G, Capuano R, De Giglio L, Logoteta A, Pozzilli C, Tedeschi G, Bonavita S.

Mult Scler Relat Disord. 2019 Jan;27:239-246. doi: 10.1016/j.msard.2018.10.113. Epub 2018 Nov 5.

2.

e-Health and multiple sclerosis: An update.

Lavorgna L, Brigo F, Moccia M, Leocani L, Lanzillo R, Clerico M, Abbadessa G, Schmierer K, Solaro C, Prosperini L, Tedeschi G, Giovannoni G, Bonavita S.

Mult Scler. 2018 Nov;24(13):1657-1664. doi: 10.1177/1352458518799629. Epub 2018 Sep 19.

PMID:
30231004
3.

Fake news, influencers and health-related professional participation on the Web: A pilot study on a social-network of people with Multiple Sclerosis.

Lavorgna L, De Stefano M, Sparaco M, Moccia M, Abbadessa G, Montella P, Buonanno D, Esposito S, Clerico M, Cenci C, Trojsi F, Lanzillo R, Rosa L, Morra VB, Ippolito D, Maniscalco G, Bisecco A, Tedeschi G, Bonavita S.

Mult Scler Relat Disord. 2018 Oct;25:175-178. doi: 10.1016/j.msard.2018.07.046. Epub 2018 Jul 31.

4.

The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.

Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA, Goettl VM, Tran M, Harrington BK, Rogers KA, Awan FT, Maddocks K, Andritsos L, Lehman AM, Sampath D, Lapalombella R, Eathiraj S, Abbadessa G, Schwartz B, Johnson AJ, Byrd JC, Woyach JA.

Cancer Discov. 2018 Oct;8(10):1300-1315. doi: 10.1158/2159-8290.CD-17-1409. Epub 2018 Aug 9.

PMID:
30093506
5.

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, Pastorelli D, Reig M, Knox J, Negri F, Trojan J, López López C, Personeni N, Decaens T, Dupuy M, Sieghart W, Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, Bruix J.

Lancet Oncol. 2018 May;19(5):682-693. doi: 10.1016/S1470-2045(18)30146-3. Epub 2018 Apr 3.

PMID:
29625879
6.

In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).

Ranieri C, Di Tommaso S, Loconte DC, Grossi V, Sanese P, Bagnulo R, Susca FC, Forte G, Peserico A, De Luisi A, Bartuli A, Selicorni A, Melis D, Lerone M, Praticò AD, Abbadessa G, Yu Y, Schwartz B, Ruggieri M, Simone C, Resta N.

Neurogenetics. 2018 May;19(2):77-91. doi: 10.1007/s10048-018-0540-1. Epub 2018 Mar 16.

7.

Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma.

Jilkova ZM, Kuyucu AZ, Kurma K, Ahmad Pour ST, Roth GS, Abbadessa G, Yu Y, Schwartz B, Sturm N, Marche PN, Hainaut P, Decaens T.

Oncotarget. 2018 Jan 23;9(13):11145-11158. doi: 10.18632/oncotarget.24298. eCollection 2018 Feb 16.

8.

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.

Papadopoulos KP, El-Rayes BF, Tolcher AW, Patnaik A, Rasco DW, Harvey RD, LoRusso PM, Sachdev JC, Abbadessa G, Savage RE, Hall T, Schwartz B, Wang Y, Kazakin J, Shaib WL.

Br J Cancer. 2017 Nov 21;117(11):1592-1599. doi: 10.1038/bjc.2017.330. Epub 2017 Oct 3.

9.

Social Media and Multiple Sclerosis in the Posttruth Age.

Lavorgna L, Lanzillo R, Brescia Morra V, Abbadessa G, Tedeschi G, Bonavita S.

Interact J Med Res. 2017 Sep 27;6(2):e18. doi: 10.2196/ijmr.7879.

10.

ARQ 087 inhibits FGFR signaling and rescues aberrant cell proliferation and differentiation in experimental models of craniosynostoses and chondrodysplasias caused by activating mutations in FGFR1, FGFR2 and FGFR3.

Balek L, Gudernova I, Vesela I, Hampl M, Oralova V, Kunova Bosakova M, Varecha M, Nemec P, Hall T, Abbadessa G, Hatch N, Buchtova M, Krejci P.

Bone. 2017 Dec;105:57-66. doi: 10.1016/j.bone.2017.08.016. Epub 2017 Aug 18.

PMID:
28826843
11.

In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy.

Wang J, Chandrasekhar V, Abbadessa G, Yu Y, Schwartz B, Kontaridis MI.

PLoS One. 2017 Jun 5;12(6):e0178905. doi: 10.1371/journal.pone.0178905. eCollection 2017.

12.

Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma.

Roth GS, Macek Jilkova Z, Zeybek Kuyucu A, Kurma K, Ahmad Pour ST, Abbadessa G, Yu Y, Busser B, Marche PN, Leroy V, Decaens T.

Mol Cancer Ther. 2017 Oct;16(10):2157-2165. doi: 10.1158/1535-7163.MCT-16-0602-T. Epub 2017 May 31.

13.

Subchronic nandrolone administration reduces cardiac oxidative markers during restraint stress by modulating protein expression patterns.

Pergolizzi B, Carriero V, Abbadessa G, Penna C, Berchialla P, De Francia S, Bracco E, Racca S.

Mol Cell Biochem. 2017 Oct;434(1-2):51-60. doi: 10.1007/s11010-017-3036-7. Epub 2017 Apr 21.

14.

Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma.

Rimassa L, Reig M, Abbadessa G, Peck-Radosavljevic M, Harris W, Zagonel V, Pastorelli D, Rota Caremoli E, Porta C, Damjanov N, Patel H, Daniele B, Lamar M, Schwartz B, Goldberg T, Santoro A, Bruix J.

World J Gastroenterol. 2017 Apr 7;23(13):2448-2452. doi: 10.3748/wjg.v23.i13.2448.

15.

In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.

Yu Y, Hall T, Eathiraj S, Wick MJ, Schwartz B, Abbadessa G.

Anticancer Drugs. 2017 Jun;28(5):503-513. doi: 10.1097/CAD.0000000000000486.

16.

Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models.

Chilà R, Hall G T, Abbadessa G, Broggini M, Damia G.

Transl Oncol. 2017 Apr;10(2):153-157. doi: 10.1016/j.tranon.2016.12.003. Epub 2017 Feb 3.

17.

Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma.

Personeni N, Giordano L, Abbadessa G, Porta C, Borbath I, Daniele B, Van Laethem JL, Van Vlierberghe H, Trojan J, De Toni EN, Gasbarrini A, Lencioni M, Lamar ME, Wang Y, Shuster D, Schwartz B, Santoro A, Rimassa L.

Oncotarget. 2017 Feb 28;8(9):14408-14415. doi: 10.18632/oncotarget.14797.

18.

ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease.

Kim K, Li J, Barazia A, Tseng A, Youn SW, Abbadessa G, Yu Y, Schwartz B, Andrews RK, Gordeuk VR, Cho J.

Haematologica. 2017 Feb;102(2):246-259. doi: 10.3324/haematol.2016.151159. Epub 2016 Oct 6.

19.

Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation.

Hall TG, Yu Y, Eathiraj S, Wang Y, Savage RE, Lapierre JM, Schwartz B, Abbadessa G.

PLoS One. 2016 Sep 14;11(9):e0162594. doi: 10.1371/journal.pone.0162594. eCollection 2016.

20.

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.

Rimassa L, Abbadessa G, Personeni N, Porta C, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, De Toni EN, Weiss A, Miles S, Gasbarrini A, Lencioni M, Lamar ME, Wang Y, Shuster D, Schwartz BE, Santoro A.

Oncotarget. 2016 Nov 8;7(45):72622-72633. doi: 10.18632/oncotarget.11621.

21.

Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.

Yu Y, Savage RE, Eathiraj S, Meade J, Wick MJ, Hall T, Abbadessa G, Schwartz B.

PLoS One. 2015 Oct 15;10(10):e0140479. doi: 10.1371/journal.pone.0140479. eCollection 2015.

22.

Systemic effects of locally injected platelet rich plasma in a rat model: an analysis on muscle and bloodstream.

Borrione P, Grasso L, Racca S, Abbadessa G, Carriero V, Fagnani F, Quaranta F, Pigozzi F.

J Biol Regul Homeost Agents. 2015 Jan-Mar;29(1):251-8.

23.

Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers.

Rimassa L, Santoro A, Daniele B, Germano D, Gasbarrini A, Salvagni S, Masi G, Abbadessa G, Lamar M, Goldberg T, Porta C.

Tumori. 2015 Mar-Apr;101(2):139-43. doi: 10.5301/tj.5000217. Epub 2015 Mar 25.

PMID:
25838254
24.

Transient receptor potential vanilloid 1 expression and functionality in mcf-7 cells: a preliminary investigation.

Vercelli C, Barbero R, Cuniberti B, Racca S, Abbadessa G, Piccione F, Re G.

J Breast Cancer. 2014 Dec;17(4):332-8. doi: 10.4048/jbc.2014.17.4.332. Epub 2014 Dec 26.

25.

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.

Pant S, Saleh M, Bendell J, Infante JR, Jones S, Kurkjian CD, Moore KM, Kazakin J, Abbadessa G, Wang Y, Chen Y, Schwartz B, Camacho LH.

Ann Oncol. 2014 Jul;25(7):1416-21. doi: 10.1093/annonc/mdu157. Epub 2014 Apr 15.

PMID:
24737778
26.

Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial.

Rimassa L, Porta C, Borbath I, Daniele B, Finn RS, Raoul JL, Schwartz LH, He AR, Trojan J, Peck-Radosavljevic M, Abbadessa G, Goldberg T, Santoro A, Bruix J.

Hepat Oncol. 2014 Apr;1(2):181-188. doi: 10.2217/hep.14.3. Epub 2014 Jan 29. Review.

27.

Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model.

Previdi S, Scolari F, Chilà R, Ricci F, Abbadessa G, Broggini M.

PLoS One. 2013 Nov 18;8(11):e79101. doi: 10.1371/journal.pone.0079101. eCollection 2013.

28.

Experimental model for the study of the effects of platelet-rich plasma on the early phases of muscle healing.

Borrione P, Grasso L, Chierto E, Geuna S, Racca S, Abbadessa G, Ronchi G, Faiola F, Di Gianfrancesco A, Pigozzi F.

Blood Transfus. 2014 Jan;12 Suppl 1:s221-8. doi: 10.2450/2013.0275-12. Epub 2013 Jun 19.

29.

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis.

Santoro A, Simonelli M, Rodriguez-Lope C, Zucali P, Camacho LH, Granito A, Senzer N, Rimassa L, Abbadessa G, Schwartz B, Lamar M, Savage RE, Bruix J.

Br J Cancer. 2013 Jan 15;108(1):21-4. doi: 10.1038/bjc.2012.556. Epub 2013 Jan 3.

30.

Steroid resistance in nasal polyposis: role of glucocorticoid receptor and TGF-beta1.

Aversa S, Ondolo C, Abbadessa G, Piccione F, Carriero V, Fulcheri A, Lauria A, De Francia S, Racca S.

Rhinology. 2012 Dec;50(4):427-35. doi: 10.4193/Rhino11.256.

PMID:
23193535
31.

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A, Miles S, Gasbarrini A, Lencioni M, Cicalese L, Sherman M, Gridelli C, Buggisch P, Gerken G, Schmid RM, Boni C, Personeni N, Hassoun Z, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME, Chen Y, Porta C.

Lancet Oncol. 2013 Jan;14(1):55-63. doi: 10.1016/S1470-2045(12)70490-4. Epub 2012 Nov 20.

PMID:
23182627
32.

Rapid determination of anti-estrogens by gas chromatography/mass spectrometry in urine: Method validation and application to real samples.

Gerace E, Salomone A, Abbadessa G, Racca S, Vincenti M.

J Pharm Anal. 2012 Feb;2(1):1-11. doi: 10.1016/j.jpha.2011.09.011. Epub 2011 Oct 26.

33.

Effects of sub-chronic nandrolone administration on hormonal adaptive response to acute stress in rats.

Racca S, Piccione F, Spaccamiglio A, Carriero VM, De Francia S, Cangemi L, Esculapio P, Papotti M, Migliaretti G, Portaleone P, Di Carlo F, Abbadessa G.

Psychoneuroendocrinology. 2012 Aug;37(8):1234-47. doi: 10.1016/j.psyneuen.2011.12.017. Epub 2012 Jan 5.

34.

Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown.

Previdi S, Abbadessa G, Dalò F, France DS, Broggini M.

Mol Cancer Ther. 2012 Jan;11(1):214-23. doi: 10.1158/1535-7163.MCT-11-0277. Epub 2011 Oct 25.

35.

A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.

Rosen LS, Senzer N, Mekhail T, Ganapathi R, Chai F, Savage RE, Waghorne C, Abbadessa G, Schwartz B, Dreicer R.

Clin Cancer Res. 2011 Dec 15;17(24):7754-64. doi: 10.1158/1078-0432.CCR-11-1002. Epub 2011 Oct 5.

36.

Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib.

Abbadessa G, Rimassa L, Pressiani T, Carrillo-Infante C, Cucchi E, Santoro A.

World J Gastroenterol. 2011 May 21;17(19):2450-3. doi: 10.3748/wjg.v17.i19.2450.

37.

Ischemia/reperfusion injury is increased and cardioprotection by a postconditioning protocol is lost as cardiac hypertrophy develops in nandrolone treated rats.

Penna C, Tullio F, Perrelli MG, Moro F, Abbadessa G, Piccione F, Carriero V, Racca S, Pagliaro P.

Basic Res Cardiol. 2011 May;106(3):409-20. doi: 10.1007/s00395-010-0143-y. Epub 2010 Dec 21.

38.

The antibacterial effect of a proline-rich antibacterial peptide A3-APO.

Rozgonyi F, Szabo D, Kocsis B, Ostorházi E, Abbadessa G, Cassone M, Wade JD, Otvos L Jr.

Curr Med Chem. 2009;16(30):3996-4002. Review.

PMID:
19747127
39.

Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.

Wu J, Henderson C, Feun L, Van Veldhuizen P, Gold P, Zheng H, Ryan T, Blaszkowsky LS, Chen H, Costa M, Rosenzweig B, Nierodzik M, Hochster H, Muggia F, Abbadessa G, Lewis J, Zhu AX.

Invest New Drugs. 2010 Oct;28(5):670-6. doi: 10.1007/s10637-009-9286-9. Epub 2009 Jun 30.

PMID:
19565187
40.

Differential expression of determinants of glucocorticoid sensitivity in androgen-dependent and androgen-independent human prostate cancer cell lines.

Dovio A, Sartori ML, De Francia S, Mussino S, Perotti P, Saba L, Abbadessa G, Racca S, Angeli A.

J Steroid Biochem Mol Biol. 2009 Aug;116(1-2):29-36. doi: 10.1016/j.jsbmb.2009.04.007. Epub 2009 May 3.

PMID:
19406240
41.

Synergistic effects against post-ischemic cardiac dysfunction by sub-chronic nandrolone pretreatment and postconditioning: role of beta2-adrenoceptor.

Penna C, Abbadessa G, Mancardi D, Tullio F, Piccione F, Spaccamiglio A, Racca S, Pagliaro P.

J Physiol Pharmacol. 2008 Dec;59(4):645-59.

42.

Unsung hero Robert C. Gallo.

Abbadessa G, Accolla R, Aiuti F, Albini A, Aldovini A, Alfano M, Antonelli G, Bartholomew C, Bentwich Z, Bertazzoni U, Berzofsky JA, Biberfeld P, Boeri E, Buonaguro L, Buonaguro FM, Bukrinsky M, Burny A, Caruso A, Cassol S, Chandra P, Ceccherini-Nelli L, Chieco-Bianchi L, Clerici M, Colombini-Hatch S, de Giuli Morghen C, de Maria A, de Rossi A, Dierich M, Della-Favera R, Dolei A, Douek D, Erfle V, Felber B, Fiorentini S, Franchini G, Gershoni JM, Gotch F, Green P, Greene WC, Hall W, Haseltine W, Jacobson S, Kallings LO, Kalyanaraman VS, Katinger H, Khalili K, Klein G, Klein E, Klotman M, Klotman P, Kotler M, Kurth R, Lafeuillade A, La Placa M, Lewis J, Lillo F, Lisziewicz J, Lomonico A, Lopalco L, Lori F, Lusso P, Macchi B, Malim M, Margolis L, Markham PD, McClure M, Miller N, Mingari MC, Moretta L, Noonan D, O'Brien S, Okamoto T, Pal R, Palese P, Panet A, Pantaleo G, Pavlakis G, Pistello M, Plotkin S, Poli G, Pomerantz R, Radaelli A, Robertguroff M, Roederer M, Sarngadharan MG, Schols D, Secchiero P, Shearer G, Siccardi A, Stevenson M, Svoboda J, Tartaglia J, Torelli G, Tornesello ML, Tschachler E, Vaccarezza M, Vallbracht A, van Lunzen J, Varnier O, Vicenzi E, von Melchner H, Witz I, Zagury D, Zagury JF, Zauli G, Zipeto D.

Science. 2009 Jan 9;323(5911):206-7. doi: 10.1126/science.323.5911.206. No abstract available.

PMID:
19131607
43.

Time-dependent acetylsalicylic acid effects on liver CYP1A and antioxidant enzymes in a rat model of 7,12-dimethylbenzanthracene (DMBA)-induced mammary carcinogenesis.

Girolami F, Abbadessa G, Racca S, Spaccamiglio A, Piccione F, Dacasto M, Carletti M, Gardini G, Di Carlo F, Nebbia C.

Toxicol Lett. 2008 Sep 26;181(2):87-92. doi: 10.1016/j.toxlet.2008.07.007. Epub 2008 Jul 17.

PMID:
18678235
44.

Development of a pharmacologically improved peptide agonist of the leptin receptor.

Otvos L Jr, Terrasi M, Cascio S, Cassone M, Abbadessa G, De Pascali F, Scolaro L, Knappe D, Stawikowski M, Cudic P, Wade JD, Hoffmann R, Surmacz E.

Biochim Biophys Acta. 2008 Oct;1783(10):1745-54. doi: 10.1016/j.bbamcr.2008.05.007. Epub 2008 May 21.

45.

Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo.

Noto PB, Abbadessa G, Cassone M, Mateo GD, Agelan A, Wade JD, Szabo D, Kocsis B, Nagy K, Rozgonyi F, Otvos L Jr.

Protein Sci. 2008 Jul;17(7):1249-55. doi: 10.1110/ps.034330.108. Epub 2008 Apr 15.

46.

Antiangiogenic drugs currently used for colorectal cancer: what other pathways can we target to prolong responses?

Abbadessa G, Vogiatzi P, Rimassa L, Claudio PP.

Drug News Perspect. 2007 Jun;20(5):307-13. Review.

PMID:
17878958
47.

Nandrolone-pretreatment enhances cardiac beta(2)-adrenoceptor expression and reverses heart contractile down-regulation in the post-stress period of acute-stressed rats.

Penna C, Abbadessa G, Mancardi D, Spaccamiglio A, Racca S, Pagliaro P.

J Steroid Biochem Mol Biol. 2007 Oct;107(1-2):106-13. Epub 2007 May 29.

PMID:
17611100
48.

The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study.

Carnaghi C, Santoro A, Rimassa L, Doci R, Rosati R, Pedicini V, Gullo G, Zuradelli M, Abbadessa G, Morenghi E, Marcon I, Garassino I.

Invest New Drugs. 2007 Oct;25(5):479-85. Epub 2007 May 11.

PMID:
17492399
49.

Viral infections as a cause of cancer (review).

Carrillo-Infante C, Abbadessa G, Bagella L, Giordano A.

Int J Oncol. 2007 Jun;30(6):1521-8. Review.

PMID:
17487374
50.

A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo.

Bagella L, Sun A, Tonini T, Abbadessa G, Cottone G, Paggi MG, De Luca A, Claudio PP, Giordano A.

Oncogene. 2007 Mar 22;26(13):1829-39. Epub 2006 Oct 16.

PMID:
17043661

Supplemental Content

Loading ...
Support Center